The levels of CX3CL1, CXCL1, CXCL5, CXCL6, CXCL11, CXCL12, CXCL13, CCL1, CCL3, CCL8, CCL11, CCL13, CCL20, CCL24, CCL25, CCL26, CCL27 and MMP-7 in WF harvested from patients with infiltrative mammary carcinoma tended to be higher than that from carcinoma in situ (Table 4). This evidence concerns the gene CXCL12 and in situ carcinoma.